Upcyte Technologies

Upcyte Technologies, founded in 2010 and based in Hamburg, Germany, is a provider of advanced cell-based research tools. Its core innovation is the upcyte® technology, which expands primary human cells (like hepatocytes and endothelial cells) to generate large, consistent quantities while maintaining a differentiated, non-cancerous phenotype. The company serves the research, screening, and drug development markets with its expanded primary cells and related media, as well as offering custom cell line development (ixcyte®) services. It emphasizes quality, operating under a QMS compliant with ISO 13485:2016.

Proprietary upcyte® technology uses controlled viral gene transfer to drive primary human cells into reversible proliferation without immortalization, preserving their differentiated phenotype for scalable, consistent production.

Upcyte competes with traditional primary cell suppliers (e.g., Lonza, Thermo Fisher) and companies developing alternative advanced models like induced pluripotent stem cell (iPSC)-derived cells. Its differentiation lies in offering primary-like cells with the scalability of a cell line.